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ABSTRACT  
Objectives The commonest secondary cause for trigeminal neuralgia (TN) is 
multiple sclerosis (MS) and little is known about this group of patients in terms of 
their presentation and treatments.  We compared patients with TN and MS 
(pwTNMS) with a cohort of patients with primary TN, who had been referred to the 
same specialist unit, both in terms of characteristics and impact on quality of life at 
the time of their first assessment.  
 
Methods Using a prospective patient database we extracted key clinical data and 
results from psychometrically tested questionnaires of 26 pwTNMS and compared 
them to an age and gender-matched set of 68 patients with primary TN. 
 
Results Our findings suggest that pwTNMS exhibit a more severe clinical phenotype 
than primary TN. Prior to referral, pwTNMS are more likely to have used more 
healthcare services  and undergone more neurosurgical interventions. Strikingly, 
pwTNMS exhibit reduced lengths and duration of remission periods and fewer 
identifiable triggers. Furthermore, pwTNMS report significant impact on quality of life 
comparable to those in primary TN, scoring highly in measures of anxiety, 
depression, and catastrophizing, but also report greater sleep disturbance, and 
overall interference in activities of daily living. 
 
Conclusions: pwTNMS have a more intractable TN, one which may necessitate a 
more complex approach to treatment, earlier referral to secondary care and an 
extensive assessment of mental health. Quality of life in pwTNMS is severely 
affected by both their MS and their TN, suggesting management should occur in 
specialist centres with access to a multidisciplinary team.   
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BACKGROUND 
 
Trigeminal Neuralgia (TN) is a chronic, and severe pain syndrome characterised by 
unilateral episodic facial pain. It is a debilitating condition whose aetiology remains 
poorly understood. Most cases of TN are idiopathic or due to compression of the 
trigeminal nerve by vessels in the posterior fossa (classical TN)1, collectively referred 
to as primary TN.  A minority are attributable to known pathologies, including 
external compression of the nerve by tumours or vascular malformations, pontine 
infarcts and inflammatory conditions like multiple sclerosis. Multiple sclerosis (MS) is 
a degenerative neurological condition characterised by widespread cerebral 
inflammation and progressive demyelination of the central nervous system. MS is 
associated with a 20-fold higher prevalence of TN. A recent review of the literature 
shows that up to 4% of MS patients are likely to have TN. The TN in the majority 
appears after MS but up to 10% report TN as the first sign of MS and it can predate 
a second MS episode by up to 10 years2. In these patients, the clinical presentation 
of TN is grossly similar as for the primary form, although more prolonged background 
pain and atypical features are reported3- 4, more women are affected, and the age of 
onset appears to be lower (45 years as compared to 50-60 years). Only De Simone 
et al 3 have compared clinical characteristics, and only between 15 patients with TN 
and MS (pwTNMS ) and 13 patients with TN only. While other reported case series 
exist Rushton  & Olafson5  - 35 cases, Jensen  et al6-  22 cases, Hooge & Redekop7  
– 35, these provide no details regarding the impact of TN on quality of life nor its 
management.     
 
As the TN of MS may  arises from different pathological mechanisms than the primary 
form, its management might need to reflect this. However, a recent systematic review 
on the management of patients pwTNMS found that there is insufficient and poor-
quality evidence to advise how this specific sub-population of TN should be managed. 
The review concluded that no specific pharmacological treatment can currently be 
advised, and that pwTNMS should therefore be managed in the same manner as non-
MS TN2.  
 
This study aims to describe the clinical, psychological, pharmacological and surgical 
profiles of a cohort of pwTNMS and compare them to a cohort of primary TN patients 
to determine if there are significant differences in initial presentation to a specialist 
facial pain unit.  
 
 
METHOD  
 
Participants 
All patients included in the study were diagnosed with TN after their first visit to a 
specialist facial pain unit in a London teaching hospital and were previously diagnosed 
with MS (by a neurologist using MRI and CSF for confirmation).  
 
Data collection 
Data for these patients were extracted from a prospective cohort of TN collected 
between 2007-2016. Data on the non-MS cohort has been published and was used to 
match the patient cohort by age and gender8. All patients were seen by the same 
clinician, JZ. Data collection was performed by two medical students and a senior 
investigator and any differences during data extraction where discussed by the team.  
 
Measures  
Data was derived from patient notes, letters and self-report questionnaires completed 
at the first visit. Basic data such as education level and profession were recorded. 
Data on the length, location and type of TN attacks reported on the visit day were 
recorded. Exacerbating or provoking factors, site, and effect on mood of pain were 
obtained. Duration of MS was calculated as the number of years from year of diagnosis 
of MS to first visit date. The same method was applied for calculating duration of TN. 
The same questionnaires used for the non-MS cohort to gauge information regarding 
pain were used here, including the Graded Chronic Pain Scale, Pain Catastrophizing 
Scale, Brief Pain Inventory, and McGill Pain Questionnaire8. The maximum daily 
dosage of current and previous medication taken for the patients’ TN symptoms as 
well as previous surgery for TN were also recorded. Patient information for the MS 
clinic was used when required. The data was entered on an Excel spreadsheet using 
the same format as for the non-MS data. Control data was taken from the previous 
non-MS cohort matched for age and gender to the pwTNMS cohort8. Multiple controls 
might be matched for one pwTNMS. 
 
Statistical analysis 
Descriptive statistics were used to summarize the pwTNMS and TN respectively. 
Mean and standard deviation were used for continuous variables if they were normally 
distributed, otherwise median and interquartile range were used. Frequency and 
percentage were used for categorical variables.  
 
Two-sample T-test or Mann-Whitney U test were used to compare the difference for 
continuous variables between pwTNMS and TN, and Fisher Exact Test or Chi-square 
test were used to compare the difference for categorical variables. Significance level 
was set at 5%. All analyses were performed in R version 3.4.1 (http://cran.r-
project.org/). 
 
RESULTS 
 
The database of patients registered between 2007-2016 contained 279 patients with 
classical TN, TN and concomitant pain, and TN with autonomic features. Of these, 33 
patients were reported as having TN and MS. Seven patients were excluded as three 
did not have confirmed MS, three had neuropathic facial pain but not TN, and one  was 
too severely affected by MS to give a history or complete questionnaires. This left 26 
patients.  
 
Nine pwTNMS had previously undergone surgery (three of them more than once), with 
mixed results. Only two achieved complete pain relief for any period of time: one after 
microvascular decompression (one-year pain relief) and one after glycerol rhizotomy 
(two years pain relief; however, repeating the surgery yielded no relief).  One patient 
underwent three glycerol rhizotomies, which were only partially successful, while 
another received Gamma knife surgery, which afforded no pain relief. Radiofrequency 
thermocoagulation provided some pain relief for three patients, one of whom had a 
repeat procedure which provided no further relief. In one patient, pulsed 
radiofrequency performed by a pain specialist was ineffective. The final patient had 
peripheral surgery, cryosurgery, performed by an oral surgeon with only partial pain 
relief.  
 
Table 1 summarises the basic characteristics of our TN patient cohorts. While grossly 
similar, there exist some significant differences between the two. PwTNMS were more 
likely than TN patients  to have had previous contact with GP services (100% pwTNMS 
vs. 80.9% TN; p = 0.039), and neurologists (53.8% vs. 29.4%; p = 0.049), as well as 
to have already had other procedures at presentation to our clinic (38.5 % vs. 13.2%; 
p = 0.015). There were also significant differences in the socioeconomic status of the 
two cohorts, specifically their deprivation index scores (p = 0.047) and employment 
status (p = 0.002).   
 
Table 1      Characteristics for patients with TNMS and TN.  
Characteristic 
pw TNMS  
n = 26 (%) 
TN 
n = 68 (%) 
P-
value 
Age in years, mean (SD) 61.35 (8.60) 61.50 (5.88) 0.921 
Age at first attack, median [IQR] 
53.00 [48.50, 
59.00] 
57.00 [50.75, 
62.00] 0.239 
Duration of TN in years, median [IQR] 5.00 [3.25, 9.50] 4.00 [2.00, 7.00] 0.214 
Duration of MS years 15.5 [11.25, 24.75] -  
Interval between MS and TN [IQR] years  9.0 [3.50, 19.50] -  
Type of MS    
     Benign MS 3 (11.5) -  
     Primary progressive 8 (30.8) -  
     Secondary progressive 7 (26.9) -  
     Relapsing-remitting 8 (30.8) -  
Female 20 (76.9) 54 (79.4) 1.000 
Index of multiple deprivation    
     1 (least deprived) 3 (12.0) 18 (26.5)  
 
0.047 
 
 
     2 10 (40.0) 10 (14.7) 
     3 3 (12.0) 20 (29.4) 
     4 6 (24.0) 13 (19.1) 
     5(most deprived) 3 (12.0) 7 (10.3) 
     Missing 1 (5.6) - 
Profession classification    
   Higher managerial, administrative and 
professional occupations 0 (0.0) 7 (10.6) 
 
 
 
 
 
 
 
0.181 
   Intermediate occupations 1 (5.6) 13 (19.7) 
   Lower managerial, administrative and 
professional occupations 6 (33.3) 25 (37.9) 
   Lower supervisory and technical 
occupations 1 (5.6) 1 (1.5) 
   Routine occupations 1 (5.6) 5 (7.6) 
   Semi-routine occupations 8 (44.4) 12 (18.2) 
   Small employers and own account workers 1 (5.6) 3 (4.5) 
   Unemployed 0 (0.0) 7 (10.6) 
   Missing 8 (30.8) - 
Employment status    
 
 
0.002 
 
   Employed full time 2 (7.7) 25 (36.8) 
   Employed part time 3 (11.5) 8 (11.8) 
   Full time homemaker 6 (23.1) 4 (5.9) 
   Retired 2 (7.7) 0 (0.0) 
   Unemployed 9 (34.6) 28 (41.2)  
   Missing 4 (15.4) - 
Referrer to specialist clinic    
     Dentist 3 (12.0) 13 (19.1)  
0.302 
 
     GP 11 (44.0) 33 (48.5) 
     Specialist 1 (4.0) 0 (0.0) 
     Missing 11 (42.3) - 
Family history of TN 2 (7.7) 4 (5.9) 0.620 
Previous services used multiple times     
     GP 26 (100.0) 55 (80.9) 0.039 
     Dentist 14 (53.8) 50 (73.5) 0.113 
Dental Service    
     Dental Specialist 2 (7.7) 11 (16.2) 0.464 
     Oral Surgeon (cryosurgery        
procedures) 3 (11.5)  16 (23.5) 0.314 
Dental Procedures 4 (15.4) 3 (4.4) 0.170 
Medical Service    
     ENT surgeon 0 (0.0) 6 (8.8) 0.274 
     Neurosurgeon 8 (30.8) 11 (16.2) 0.633 
     Neurologist 14 (53.8) 20 (29.4) 0.049 
     Physician 0 (0.0) 5 (7.4) 0.364 
     Psychiatrist 0 (0.0) 1 (1.5) 1.000 
     Psychologist 2 (7.7) 0 (0.0) 0.130 
     Pain Specialist  5 (19.2) 6 (8.8) 0.296 
Other medical procedures 10 (38.5) 9 (13.2) 0.015 
No. of secondary dental or medical 
services for TN  
  
     0 3 (11.5) 15 (22.1)  
 
0.651 
 
     1 15 (57.7) 34 (50.0) 
     2 7 (26.9) 15 (22.1) 
     3+ 1 (3.8) 4 (5.9) 
Note: values are presented as frequency (%); P-value represents comparison between two 
groups; missing values are not included.  
 
While the characteristics of the pain were broadly comparable between the two 
cohorts, there were also some significant differences, as shown in Table 2. Most 
notably, the pwTNMS exhibited significantly reduced lengths of remission (p = 
0.008), with 46.2% of this group reporting “no remission”, as compared to only 5.2% 
of the TN group. Despite having fewer remissions, pwTNMS reported fewer 
instances of prolonged pain after an acute attack, as compared with TN patients 
(11.5% vs. 47.5%; p = 0.011). 
 
The anatomical distribution of the pain was similar, with both cohorts experiencing 
third division distribution as the major focus of pain. Of these, ten reported only lower 
mandibular area with no extension above the ear. Just under half of pwTNMS have 
pain in only one division, similar to primary TN, and neither group had only first 
division pain. However, pwTNMS reported more bilateral pain, but this did not meet 
statistical significance. 
 
Table 2 Clinical features stratified by type of TN 
Pain characteristic Group 1 MSTN n = 26 
Group 2 TN 
 n = 68 P-trend 
V1 only 0 (0.0) 0 (0.0) - 
V2 only 3 (11.5) 15 (22.1) 0.263 
V3 only 10 (38.5) 21 (30.9) 0.622 
V1 + V2 2 (7.7) 6 (8.8) 1.0 
V2 + V3 8 (30.8) 22 (32.4) 1.0 
V1 + V2 + V3 3 (11.5) 3 (4.4) 0.428 
Right 10 (38.5) 43 (63.2) 0.053 
Left 14 (53.8) 24 (35.3) 0.160 
Bilateral 2 (7.7) 1 (1.5) 0.379 
Intra oral pain 26 (100) 58 (85.3) 0.090 
Extra oral pain  17 (65.4) 54 (100.0) 0.025 
Predominant type of 
attack    
   Single stab 12 (46.2) 28 (41.2) 
0.539 
   Series of stabs 5 (19.2) 23 (33.8) 
   Saw tooth 4 (15.4) 9 (13.2) 
   Single stab + Series of 
stabs 5 (19.2) 8 (11.8) 
Pain severity, median 
[IQR] scale 0-10 
   
   Worse 10.00 [8.00, 10.00] 10.00 [8.00, 10.00] 0.891 
   Average 5.00 [3.00, 7.00] 5.00 [3.00, 7.00] 0.682 
   Least 1.00 [0.00, 3.00] 2.00 [0.00, 5.00] 0.049 
Circumstances     
   Acute onset 6 (23.1) 19 (32.2) 
0.682 
   Memorable onset 11 (42.3) 25 (42.4) 
   Slow to develop 6 (23.1) 11 (18.6) 
   Cannot remember onset 3 (11.5) 4 (6.8) 
Frequency of pain attack    
   Daily 16 (88.9) 48 (90.6) 1.000 
Duration of attacks     
   Seconds 20 (76.9) 40 (59.7) 
0.089    Minutes 3 (11.5) 23 (34.3) 
   1-4 hours 3 (11.5) 4 (6.0) 
Pain after main attack 3 (11.5) 29 (47.5) 0.011 
Length of remission    
   None 9 (34.6) 3 (5.2) 
0.013 
   Days 0 (0.0) 6 (10.3) 
   Weeks 4 (15.4) 8 (13.8) 
   Months 10 (38.5) 33 (56.9) 
   Years 2 (9.5) 8 (13.8) 
   Missing (but in 
remission) 1 (3.85)  
 
Remission period 
change (% of 
participants who have 
had remission) 
n= 17 n= 55/59  
   No change 1 (6.25) 15 (25.4) 
0.753    Shorter remission 12 (75.0) 40 (67.8) 
   Longer remission 2 (12.5) 4 (6.8) 
   Missing 1 (6.25) -  
Provoking factors     
Provoked by ≥1 light touch 
stimuli 24 (92.3) 66 (97.1) 0.998 
Intraoral triggers (eating 
and/or brushing teeth) 25 (96.1) 63 (92.6) 0.241 
Provoked by other factors    
   Cold wind/weather 9 (34.6) 26 (38.2) 0.931 
   Bodily movement 8 (30.8) 29 (42.6) 0.413 
   Noise or light 1 (3.8) 0 (0.0) 0.616 
    
McGill pain 
questionnaire     
   Number of words chosen 
(mean ± sd) 
10.6 (4.0) 10.9 (3.8) 0.672 
    
   Sensory groups Stabbing (21) Stabbing (27)  
 Shooting (19) Shooting (51)  
 Sharp (14) Sharp (43)  
   Affective Terrifying (12) Fearful (17)  
 Vicious (9) Vicious (23)  
   Evaluative Unbearable (17) Unbearable (24)  
   Miscellaneous Piercing (18) Piercing (23)  
Note: values are presented as frequency (%); P-value represents comparison 
between two groups; missing values are not included. 
 
 
The medical histories (Table 3) were broadly similar between the two groups, with 
the major difference being that pwTNMS were much more likely to have had surgery 
prior to referral (53.8% vs.10.3%; p < 0.001) and were much more likely to report 
disturbances to their sleep (50% vs. 14.9%; p = 0.001). Other differences included 
an increased incidence of migraines and tension-type headaches, cardiovascular 
disease, neck pain, dental problems and disturbed salivation amongst pwTNMS. 
 
Table 3     Associated factors and medical history in TN patients  
 
Associate factors and  
medical history 
Group 1  
MS TN  
n = 26 
Group 2 
TN  
n = 68 
P-trend 
Altered sensation or 
numbness 9 (34.6) 15 (22.4) 0.344 
Disturbed salivation 9 (34.6) 7 (10.6) 0.015 
Dental problem 7 (26.9) 3 (4.5) 0.006 
Affects sleep 13 (50.0) 10 (14.9) 0.001 
Any autonomics unilateral 16 (61.5) 50 (73.5) 0.376 
   Swelling face 3 (11.5) 9 (13.4) 1.000 
   Redness of the face  4 (15.4) 7 (10.4) 0.712 
   Nasal stuffiness/runny 5 (19.2) 16 (23.9) 0.838 
   Eye redness 5 (19.2) 5 (7.5) 0.204 
   Eye tearing  7 (26.9) 14 (20.9) 0.728 
   Oedema eyelid 2 (7.7) 1 (1.5) 0.387 
   Earache 4 (15.4) 7 (10.4) 0.761 
   Ringing ears 5 (19.2) 9 (13.4) 0.705 
   Fullness ears 3 (11.5) 6 (9.0) 1.000 
Headaches    
Migraines 6 (23.1) 11 (16.7) 0.678 
Migraines + TTH 5 (19.2) 2 (2.9) 0.024 
Bruxism 11 (42.3) 17 (26.2) 0.209 
Medical history    
Hypertension 7 (26.9) 25 (36.8) 0.766 
CVS 5 (19.2) 3 (4.4) 0.035 
Diabetes 0 (0.0) 3 (4.4) 0.665 
Deafness 4 (15.4) 4 (6.0) 0.298 
Other chronic pain 9 (34.6) 16 (23.5) 0.408 
   Neck pain 8 (30.8) 6 (9.2) 0.024 
   Back pain 5 (19.2) 11 (16.7) 1.000 
Previous surgery TN 14 (53.8) 7 (10.3) <0.001 
 
Note: values are presented as frequency (%); P-value represents comparison 
between two groups; missing values are not included. CVS- cardiovascular 
problems; TTH- Tension type headaches  
 
 
Both pwTNMS and TN patients similarly reported that their pain has a considerable 
impact on activities of daily living and their psychosocial wellbeing, with many 
patients scoring high on assessments of both anxiety and depression (table 4).  
 
Table 4 Impact of trigeminal neuralgia on quality of life  
 
Scale pw TNMS TN  P-value  
Chronic graded pain scale  n=24 n=54  
Grade 1 4 (16.7) 8 (14.8) 0.024 
Grade 2 2 (8.3) 22 (40.7) 
Grade 3 6 (25.0) 7 (13.0) 
Grade 4 12 (50.0) 17 (31.5) 
Days off normal activities  n=23 n=59  
0-6 5 (21.7) 25 (42.4) 0.154 
7-14 3 (13.0) 9 (15.3) 
15-30 4 (17.4) 16 (27.1) 
31+ 11 (47.8) 9 (15.3) 
PC scale total score, median 
(IQR) 
41.5 [33.5,47.5] 30 [17, 42] 0.201 
Pain catastrophizing score n=20 n=55  
Score over 20 17 (85.0%) 36 (65.5) 0.532 
HAD-Anxiety n=25 n=60  
   Nil 11 (46.2) 22 (36.7) 0.151 
   Mild 6 (23.1) 26 (43.3) 
   Severe 8 (30.8) 12 (20.0) 
HAD-Depression n=26 n=60  
   Nil 11 (44.0) 40 (66.7) 0.136 
   Mild 4 (16.0) 9 (15.0) 
   Severe 10 (40.0) 11 (18.3) 
Brief pain inventory, median 
[IQR] 
n=25 n=68  
   Pain severity average index 3.67 [2.33, 6.67] 3.75 [1.81, 
5.69] 
0.718 
   Pain interference- general daily 
life 
4.71 [1.43, 6.71]  2.29 [0.57, 5.
00] 
 
0.266 
   Pain interference- facial status 5.64 [2.82, 7.93]  
 
4.71 [1.21, 
8.00] 
0.356 
Note: values are presented as frequency (%); P-value represents comparison 
between two groups; missing values are not included. 
 
Scores over 20 on the Pain Catastrophizing Score indicate significant negative 
thoughts and the majority of patients in both cohorts exhibited this (85% and 65.5%; 
p = 0.201). The major difference between the two groups was on the Chronic Graded 
Pain Scale (p=0.024), where pwTNMS scored more frequently in grades 3/4 (high-
disability) while TN patients were more frequently grades 1/2 (low-disability).  
 
Figure 1a and b  shows the results from the Brief Pain Inventory including the more 
specific facial extended one  and highlights the  significant impact on quality of life 
especially in facial activities and is  similar to the TN group8. 
 
Figure 1a and b  HERE  Brief Pain Inventory in patients with TNMS  
 
 
 
 
 
 
Both cohorts of patients have trialed a wide variety of drugs, as seen in Table 5. The 
majority of patients have used carbamazepine (pwTNMS 21 vs. TN 53), which 
represents the most commonly used drug. Following carbamazepine use is 
gabapentin (pwTNMS 13 vs.TN 20) and then pregabalin (pwTNMS 5 vs TN 9)  and 
oxcarbazepine (pwTNMS 5 vs. TN 8).  Other drugs included Tizanidine and 
prednisolone.  
 
Table 5    Drugs used prior to referral 
 
 pwTNMS  (n = 
26) 
TN (n = 68) P-value 
No of 
anticonvulsants  
   
0 1 (3.8) 4 (5.9) 0.241 
1 6 (23.1) 19 (27.9) 
2 13 (50.0) 21 (30.9) 
3 3 (11.5) 12 (17.6) 
4+ 3 (11.5) 12 (17.6) 
Opioids 4 (15.4) 9 (13.2) 0.749 
OTC + analgesics  5 (19.2) 18 (26.5) 0.595 
Muscle relaxant 
baclofen  7 (26.9) 16 (23.5) 
 
Antidepressants any 12 (46.2) 4 (5.9) <0.001 
Antibiotics  1 (3.8) 19 (27.9) 0.011 
Other 2 (7.7) 1 (1.5) 0.184 
 
Note: values are presented as frequency (%); P-value represents comparison 
between two groups; missing values are not included. OTC- over the counter 
medications  
 
 
 
DISCUSSION 
 
To our knowledge, this is the first study to document the impact of TN on patients 
with MS and to compare this group to those with primary TN. While the two groups 
share many similarities, as outlined above, we have found several domains in which 
they differ, differences which suggest that pwTNMS exhibit a more severe phenotype 
than TN. The severity of pwTNMS is shown by their increased use of healthcare 
services, the features of the pain, and the secondary impact of that pain on their 
physical and mental wellbeing.  
 
PwTNMS may require and rely on healthcare services more than their TN 
counterparts. At presentation to our clinic, every single one of our pwTNMS reported 
having used GP services to attempt to manage their pain, while this was true for a 
majority, but not the entirety of our TN cohort who may come through the dental 
route due to the frequent presentation in the lower mandibular area. This cohort had 
comparatively higher rates of interventions prior to presentation, and, specifically, 
higher rates of neurosurgery than TN patients. Notably, neurosurgery provided relief 
only to a minority of patients, and even then only for limited amounts of time, in 
accordance with a recent systematic review of the management of pwTNMS2.  
 
With regards to the clinical features of pwTNMS, the most striking difference was the 
reduced length and duration of remissions that these patients suffered from. A 
majority of pwTNMS reported either no remissions (46.2%) or only weeks of 
remission (11.5%), despite the majority of TN patients reporting months to years of 
remission. Moreover, pwTNMS exhibited fewer identifiable triggers to acute attacks, 
complicating preventative measures. This is likely reflective of the underlying disease 
process of MS, which is characterized by often unpredictable flare ups. Like TN 
patients, pwTNMS also tend to trial many types of drugs, reflecting the common 
difficulty in achieving pharmacological control of symptoms. 
 
 
There exists limited literature on the impact of TN on wellbeing, but these few 
published papers highlight a notable impact on anxiety, depression and sleep8-10. 
This study shows that a comparable level of disability is noted in pwTNMS. 
Significant disruptions to activities of daily living are noted for all TN patients but 
these appear higher in pwTNMS, especially with regards to disturbances to sleep. 
On the Chronic Graded Pain Scale pwTNMS suffered greater interference in 
activities of daily living due to pain than TN patients. However, this conclusion is 
complicated by the difficulty in distinguishing pain due to TN from other pain that 
commonly occurs in MS patient, the prevalence and course of which is poorly 
described11. We did not ascertain their status on the Expanded Disability Status 
Scale (EDSS), which may have provided further information.  
 
At first presentation, our TNMS cohort was similar in age to patients with primary TN, 
in keeping with other studies2. On average, symptoms first occurred in the 5th 
decade of life, although this is in contrast to De simone et al3 who found the mean 
age of onset to be 43 years, albeit in a smaller cohort of 15 pwTNMS. In this cohort, 
all patients first presented with MS, but a review of the literature based on 950 
patients has shown that 10.5% have TN before MS, and the gap between the 
diagnosis of MS and TN could be 10 years. Cruccu et al4 suggests that MS starts 
later in those who develop TN, but we could not validate this in our dataset . 
 
From this baseline data it appears that pwTNMS have a more intractable TN, one 
which may necessitate a more complex approach to treatment, earlier referral to 
secondary care and a thorough assessment of mental health. Heinskou et al12 have 
previously suggested that this cohort needs a multidisciplinary approach, and our 
findings support this. This should potentially include psychological support on how to 
manage fear, isolation and the unpredictability of flare ups. For example, a recent 
review by Simpson et al13 has shown that mindfulness-based interventions may 
benefit patients with MS in terms of quality of life and mental health. 
 
Limitations  
 
Cruccu et al4 suggest that abnormal blink reflexes show good specificity and 
sensitivity in differentiating between TN and pwTNMS, but these were not carried out 
with this group. This series, while larger than previous studies, remains small, 
therefore limiting the strength of the conclusions we have drawn. Moreover, detailed 
data on imaging was not available, which may be important as diffusivity studies 
(Diffusion MRI tractography) begin to differentiate the microstructure of MSTN14. 
Truini et al15 also highlight that in pwTNMS both demyelination and compression can 
be present. We have not been able to link disease progression with MS progression 
or drug usage as the numbers are too small.  
 
Future  
Larger series will need to be studied. Registries such as those held by the MS 
Society UK show that up to 15% of their patients (1,800) report having TN, providing 
a potential pool of data. Enlarging the database and collecting longitudinal data 
would make it possible to determine if the TNMS care-pathway needs to be different 
from those of TN, with particular emphasis on how different treatments impact on 
quality of life and mental health. Currently there is no data to determine if 
management of MS impacts in any way with long term TN outcomes.  Data from 
Scandinavian countries suggests that overall MS patients have a shortened life 
expectancy although it is now improving16 and many live with 20 years moderate and 
30 years severe disability17 and TN can add to this burden. 
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